Three hundred eighty-four patients with stage III ( @ % ) and IV ( @ % ) oropharyngeal ( @ % ) , hypopharyngeal ( @ % ) , and oral cavity ( @ % ) cancer were randomly assigned to @Gy/@Gy daily followed by twice-daily @ Gy to a total of @ Gy concurrently with mitomycin C/@-FU ( C-HART ) or @Gy/@Gy daily followed by twice-daily @ Gy to a total dose of @ Gy alone ( HART ) .